The market may be down 23% this year, but that hasn't stopped a trio of drug companies from powering onward. Vertex Pharmaceuticals , (NASDAQ: VRTX) Catalyst Pharmaceuticals , (NASDAQ: CPRX) and Corcept Therapeutics (NASDAQ: CORT) are all rising sharply in contrast to the market and other biopharma businesses.
So how are they doing it, and are they likely to continue outperforming? In a nutshell, all three players develop medicines to treat rare diseases like cystic fibrosis (CF), Lambert-Eaton Myasthenic Syndrome (LEMS), and Cushing's syndrome -- and all three are profitable and growing.
Let's examine why their tightly focused business models are probably sufficient to keep the good times rolling for investors, even if the bear market drags on.
For further details see:
These 3 Stocks Are Winning the Bear Market -- Here's How